JP Morgan Private Wealth Advisors’s Blueprint Medicines BPMC Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$203K	Buy	4,040 +77	+2%	+$4.12K	﹤0.01%	1628
2023 Q2	$250K	Buy	+3,963	New	+$215K	﹤0.01%	1312
2023 Q1	–	Sell	-4,831	Closed	-$212K	–	1945
2022 Q4	$212K	Sell	4,831 -27	-0.6%	-$1.29K	﹤0.01%	1805
2022 Q3	$320K	Sell	4,858 -83	-2%	-$5.33K	﹤0.01%	1631
2022 Q2	$250K	Sell	4,941 -90	-2%	-$5.27K	﹤0.01%	1740
2022 Q1	$321K	Buy	5,031 +58	+1%	+$4.16K	﹤0.01%	1722
2021 Q4	$533K	Hold	4,973	–	–	﹤0.01%	1525
2021 Q3	$511K	Buy	4,973 +6	+0.1%	+$559	﹤0.01%	1492
2021 Q2	$437K	Buy	4,967 +6	+0.1%	+$550	﹤0.01%	1529
2021 Q1	$482K	Sell	4,961 -248	-5%	-$24.8K	﹤0.01%	1326
2020 Q4	$584K	Buy	5,209 +41	+0.8%	+$4.32K	﹤0.01%	1229
2020 Q3	$479K	Buy	5,168 +1,076	+26%	+$82.9K	﹤0.01%	1175
2020 Q2	$319K	Hold	4,092	–	–	﹤0.01%	1285
2020 Q1	$239K	Sell	4,092 -10	-0.2%	-$644	﹤0.01%	1225
2019 Q4	$329K	Buy	4,102 +10	+0.2%	+$749	﹤0.01%	1199
2019 Q3	$301K	Hold	4,092	–	–	﹤0.01%	1193
2019 Q2	$386K	Sell	4,092 -2,000	-33%	-$165K	﹤0.01%	1063
2019 Q1	$488K	Buy	6,092 +2,119	+53%	+$157K	﹤0.01%	1049
2018 Q4	$214K	Sell	3,973 -229	-5%	-$13.9K	﹤0.01%	1313
2018 Q3	$328K	Buy	4,202 +197	+5%	+$13.7K	﹤0.01%	1248
2018 Q2	$254K	Hold	4,005	–	–	﹤0.01%	1269
2018 Q1	$367K	Hold	4,005	–	–	﹤0.01%	971
2017 Q4	$302K	Sell	4,005 -196	-5%	-$13.8K	﹤0.01%	1053
2017 Q3	$293K	Buy	+4,201	New	+$224K	﹤0.01%	1028

Other funds holding BPMC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Private Wealth Advisors's BPMC Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors increased its Blueprint Medicines (BPMC) stake by 1.9% in Q3 2023, buying an estimated $4.12K and bringing the position to 4,040 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

JP Morgan Private Wealth Advisors first reported a position in BPMC in Q3 2017 and has held it in 24 quarters since. The position peaked at $584K in Q4 2020. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

JP Morgan Private Wealth Advisors held 4,040 shares of Blueprint Medicines worth $203K as of Q3 2023.
JP Morgan Private Wealth Advisors bought 77 Blueprint Medicines shares in Q3 2023, an estimated $4.12K.
Blueprint Medicines made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1628 holding.
JP Morgan Private Wealth Advisors first reported a position in Blueprint Medicines in Q3 2017 and has held it in 24 quarters since.
JP Morgan Private Wealth Advisors's Blueprint Medicines position peaked at $584K in Q4 2020.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.